CSPC advances cancer drug pipeline with approvals and designations

CSPC Pharmaceutical Group (HKEX:1093) is bolstering its oncology portfolio with advancements in multiple drug candidates. The company announced that its bispecific fusion protein drug, JMT106, targeting GPC3 and interferon receptors, has received clinical trial approval from China's National Medical Products Administration. This approval follows the FDA's green light in January 2024 for clinical trials in the U.S. JMT106 is designed to kill tumor cells while simultaneously activating immune regulation, showing promise in preclinical studies across various solid tumors.